# Olmesartan and an add-on Treatment in Patients With Mild to Moderate Hypertension

> **NCT00311155** · PHASE4 · COMPLETED · sponsor: **Sankyo Pharma Gmbh** · enrollment: 694 (actual)

## Conditions studied

- Essential Hypertension

## Interventions

- **DRUG:** olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessary

## Key facts

- **NCT ID:** NCT00311155
- **Lead sponsor:** Sankyo Pharma Gmbh
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-03
- **Primary completion:** 2008-04
- **Final completion:** 2008-04
- **Target enrollment:** 694 (ACTUAL)
- **Last updated:** 2010-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00311155

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00311155, "Olmesartan and an add-on Treatment in Patients With Mild to Moderate Hypertension". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00311155. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*